<div>Introduction</div><div>•Organ shortage</div><div>•Benefits to recipients of LKDT</div><div>•Ethical foundation of donor autonomy within boundaries of ‘acceptable risk’</div><div>•Brief mention of Peter Reese work on ‘harms’ that may results from declining a donor candidate</div><div>•Landscape of living donation - Epidemiology, trends </div><div><br></div><div>Informed Consent and Framework for Care</div><div>•Core principles and processes of informed consent</div><div>•Overview of the Living Donor Care Team - Roles & Responsibilities</div><div><br></div><div>Medical Evaluation</div><div>•GFR, Albuminuria, Hematuria</div><div>•Renal anatomy, Nephrolithiasis</div><div>•Blood pressure</div><div>•Metabolic</div><div>•Cancer</div><div>•Infections</div><div>•Genetics - ADPKD, ApoL1, and other less common </div><div>•Peri-operative screening</div><div><br></div><div>Compatibility, Paired Donation, and Incompatible Living Donor Transplants</div><div><br></div><div>Psychosocial Evaluation</div><div><br></div><div>Risk Assessment </div><div>•New risk calculators for donor ESRD (Grams ‘predonation’, Massie ‘postdonation’)</div><div>•New tools for recipient outcomes based on LD characteristics</div>•Pregnancy-related risks and counseling<div><br></div><div>Surgical Approaches </div><div>•Comparative data on outcomes, recovery, pain, cosmesis as per the surgical trials.</div><div><br></div><div>Follow-up Care</div><div><br></div><div>Policy & Ethics</div><div>•Core Ethical Tenets & Unacceptable practices. </div><div>•‘Incentives’/paying donors (can be brief – Declaration of Istanbul, note as illegal and most countries, etc)</div><div>•Donor Candidate identification (including emerging approaches like Social Media)</div><div>•Non-directed donors</div><div>•International donors</div><div>•Disparities in access to LKDT and strategies to less</div><div>•Mitigating barriers/disincentives to living donation – including Financial, Educational/SES/health literacy-related, etc)</div><div><br></div>